Publicacións (84) Publicacións de Ana Echarri Piudo

2024

  1. Contraceptive Recommendations for Women with Immune-Mediated Inflammatory Diseases: A Delphi Consensus

    Advances in Therapy, Vol. 41, Núm. 4, pp. 1372-1384

  2. Implementation of a Teledermatology Electronic Consultation Program to Improve the Care of Patients with Inflammatory Bowel Disease

    Telemedicine Reports, Vol. 5, Núm. 1, pp. 12-17

  3. Long-Term Evaluation of Intensified Ustekinumab in Crohn's Disease: Real-Life Results

    JOURNAL OF CROHNS & COLITIS, Vol. 18, Núm. Supl 1, pp. I1039

  4. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 774-792

2023

  1. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10

  2. Optimizing treatment of mild to moderate ulcerative colitis: CU-forum Delphi consensus

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 10, pp. 784-794

  3. Preoperative optimization of patients with inflammatory bowel disease: a multicentre study of EIGA Group

    JOURNAL OF CROHNS & COLITIS, Vol. 17, Núm. Supl 1, pp. I356

  4. Should Inflammatory Bowel Disease Clinicians Provide Their Patients with e-Health Resources? Patients' and Professionals' Perspectives

    Telemedicine journal and e-health : the official journal of the American Telemedicine Association, Vol. 29, Núm. 10, pp. 1504-1513

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

    The Lancet Gastroenterology and Hepatology, Vol. 7, Núm. 2, pp. 128-140

  3. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

    The Lancet Gastroenterology and Hepatology, Vol. 7, Núm. 2, pp. 118-127

  4. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 3, pp. 165-176

  5. TELEIBD: A telematic fast-track pathway for patients with high suspicion of Inflammatory Bowel Disease in primary care

    JOURNAL OF CROHNS & COLITIS, Vol. 16, Núm. Supl 1, pp. I314-I315

  6. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

    The Lancet Gastroenterology and Hepatology, Vol. 7, Núm. 4, pp. 294-306

2021

  1. Effectiveness of ustekinumab in fistulising perianal Crohn′s disease refractory or intolerant to anti-TNF

    Journal of Crohn's and Colitis, Vol. 15, Núm. Supplement_1, pp. S419-S420

  2. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

  3. Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa — GETECCU) on dysplasia screening in inflammatory bowel disease patients

    Gastroenterologia y Hepatologia, Vol. 44, Núm. 6, pp. 435-447

  4. Risk and predictors of surgery in a newly diagnosed cohort of IBD patients in the biologic era: Results from the EpidemIBD study

    Journal of Crohn's and Colitis, Vol. 15, Núm. Supplement_1, pp. S018-S020

2020

  1. INTRALESIONAL INJECTION OF ADALIMUMAB IN INTESTINAL STRICTURES OF PATIENTS WITH CROHN’S DISEASE: A RANDOMIZED, MULTICENTER, PROSPECTIVE CLINICAL TRIAL

    Gastrointestinal Endoscopy, Vol. 91, Núm. 6, pp. AB277

  2. The Harvey-Bradshaw Index Adapted to a Mobile Application Compared with In-Clinic Assessment: The MediCrohn Study

    Telemedicine and e-Health, Vol. 26, Núm. 1, pp. 80-88